Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia

Show other versions (1)

Introduction: Imatinib Mesylate is a selective inhibitor of TK and is considered now to be the frontline therapeutic agent during the chronic phase of CML. We have evaluated the efficacy of it on children with chronic-phase of CML. Patients and Methods: In a clinical trial study over the past 3 year...

Full description

Bibliographic Details
Main Authors:	Gholamreza Bahoush, Mardavizh Albouyeh, Parvaneh Vossough
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2009-09-01
Series:	International Journal of Hematology-Oncology and Stem Cell Research
Subjects:	Imatinib Mesylate CML Tyrosine Kinase
Online Access:	https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/217

Similar Items

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01)

Bioequivalence/bioavailability study of a new formulation of imatinib mesylate 100 mg coated tablets versus Glivec® in Brazilian healthy male volunteers in fed state
by: Carlos Eduardo Sverdloff, et al.
Published: (2023-12-01)

OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
by: Grzegorz Helbig, et al.
Published: (2015-01-01)

Study of correlation between imatinib mesylate plasma levels and hematological profile of patients undergoing treatment for chronic myeloid leukemia
by: Emanuelle S. Dal Ponte, et al.
Published: (2017-06-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor
by: Abbas Agaimy, et al.
Published: (2013-03-01)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011-03-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01)

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
by: Marjanu Hikmah Elias, et al.
Published: (2012-11-01)

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
by: Olga Meltem Akay, et al.
Published: (2016-05-01)

Melasma-like hyperpigmentation: A rare side effect of imatinib mesylate
by: Shreya Agrawal, et al.
Published: (2023-01-01)

O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe Therapy of Chronic Myeloid Leukemia with imatinib mesylate
by: Vaneuza M. Funke, et al.
Published: (2008-04-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

Outcome of imatinib mesylate in women with child-bearing age diagnosed with chronic myeloid leukemia
by: Alaa Fadhil Alwan, et al.
Published: (2021-01-01)

Generalized lichenoid drug eruption associated with imatinib mesylate therapy
by: Sudip Kumar Ghosh
Published: (2013-01-01)

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011-06-01)

Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters
by: Mervat M. Omran, MD, et al.
Published: (2022-01-01)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

Evaluation of Imatinib adherence in chronic myeloid leukemia patients in Babylon Province, Iraq
by: Athmar Kadhim Gatea, et al.
Published: (2023-01-01)

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity
by: Caterina Musolino, et al.
Published: (2015-05-01)

Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate
by: Kritamorn Jitrangsri, et al.
Published: (2023-09-01)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
by: Ana Lucia Vieira-Mion, et al.

The role of miRNA -150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients
by: Kawthar Ali Radhi, et al.
Published: (2023-03-01)

Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment
by: Claudia Bettoni da Cunha-Riehm, et al.
Published: (2020-04-01)

Chronic subdural hematoma-unsual cause of headache in a patient with chronic myeloid leukemia treated with high-dose imatinib mesylate: A rare case report with review of literature
by: Sanjay M Khaladkar, et al.
Published: (2015-01-01)

Effects of Imatinib Mesylate in Mouse Models of Multiple Sclerosis and In vitro Determinants
by: Gholamreza Azizi, et al.
Published: (2014-06-01)

Falla cardiaca asociada con el uso de imatinib mesilato: Reporte de un caso Heart failure associated to imatinib mesylate use: Case report
by: Clara Saldarriaga, et al.
Published: (2008-12-01)

Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials
by: Fateen Ata, et al.
Published: (2023-12-01)

Optimization Studies on Imatinib Mesylate Loaded Nanoliposomes Using Box-Behnken Design
by: Mandeep Dahiya, et al.
Published: (2022-03-01)

In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery
by: Xu H, et al.
Published: (2021-02-01)

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
by: Ol'ga Veniaminovna Stakhina, et al.
Published: (2010-02-01)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
by: Omar Prado-Carrillo, et al.
Published: (2022-07-01)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
by: Bożena Karolewicz, et al.
Published: (2019-07-01)

Acquisition of mixed lineage leukemia rearrangement in a chronic myeloid leukemia patient while on imatinib
by: Adriana Zámečníkova
Published: (2011-08-01)

Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: a study of 98 cases Tratamento da leucemia mielóide crônica com imatinib mesilato no Brasil: estudo de 98 casos
by: Vaneuza A. M. Funke, et al.
Published: (2005-09-01)

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
by: Monika Jaruskova, et al.
Published: (2017-04-01)